What Is the Scope of US Patent 8,597,876 and Where Does It Sit in the HIV Patent Landscape?

US Drug Patent 8,597,876 claims method-of-treatment and method-of-use coverage for HIV infection and mutant retroviral infection, centered on administration of a compound defined by a highly generalized structural formula (A) plus pharmaceutically acceptable salts, prodrugs, and esters. The claims are written to capture both (i) antiretroviral treatment-experienced patients and (ii) mutant HIV contexts, including multidrug-resistant HIV and clinically defined resistance profiles.

A core structural theme runs through the independent methods: a compound of formula A with layered variable definitions controlling:

a core scaffold (W, Q, X, Y/Z, n, m),
substituent classes on rings and linkers (R1, R2, R3, R4, R5, R6),
permissive ranges for chain length and ring size (e.g., C1-C6 alkyl, C2-C6 alkenyl; ring sizes restricted in dependent claims),
and broad tolerance for prodrug/ester/salt formatting and substitution patterns (halogens and multiple hetero-functional groups).

The landscape implication is straightforward: this patent is not a single-molecule claim set. It is a structure-driven claims engine designed to cover a family of related antivirals, then narrow by dependent claims to specific exemplified embodiments, including specific aryl substitution patterns and specific resistance-relevant protease mutations.

What Do the Independent Claims Cover?

Claim 1: Method of treating HIV infection in antiretroviral treatment-experienced mammals

Claim type: Method of treatment.
Target population: “an antiretroviral treatment-experienced mammal.”
Administration: administering an effective amount of:

a compound of formula A (or pharmaceutically acceptable salt/prodrug/ester), where formula A is elaborated by a multi-variable definition.

Biological scope (in claim 1 and dependent claims):

Treated HIV infection may be wild-type HIV (Claim 13).
Treated HIV may be mutant HIV with at least one protease mutation (Claim 14).
Treated HIV may be mutant HIV with at least one reverse transcriptase mutation (Claim 15).

Structural scope: Claim 1 defines formula A through variables R1, Y, Z, n, X, Q, R2, m, R3, R4, R5, W, R6 with extensive optional substituents.

Key structural constraints explicitly stated in Claim 1 include:

R1 is “H or” a broad set: alkyl/alkenyl/alkynyl/cycloalkyl/cycloalkylalkyl/aryl/aralkyl/heterocycloalkyl/heterocycloalkylalkyl/heteroaryl/heteroaralkyl, with optional substitution on at least one hydrogen by OR7, SR7, CN, NO2, N3, and halogen, where R7 is H or an unsubstituted hydrocarbon (alkyl/alkenyl/alkynyl).
Y and Z each independently select from a list of atom types including CH2, O, S, SO, SO2, NR8, and several amide/thiocarbonyl/oxycarbonyl variants (e.g., R8C(O)N, R8OC(O)N, R8OC(S)N, etc.). n = 1 to 5.
X is bond / substituted carbon / heteroatom / nitrogen variant:
- “X is a covalent bond, CHR10, CHR10CH2, CH2CHR10, O, NR10, or S,” where R10 is H or unsubstituted alkyl/alkenyl/alkynyl.
Q is C(O), C(S), or SO2.
R2 is H or C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl.
m = 0 to 6.
R3 is cycloalkyl/heterocycloalkyl/aryl/heteroaryl with optional substitution selected from a set that includes alkyl, (CH2)pR11, OR12, SR12, CN, N3, NO2, NR12R13, C(O)R12, C(S)R12, CO2R12, and halogen, with p = 0 to 5 and R11 as a cycloalkyl/heteroaryl/aryl with permitted substitutions (halogen, OH, OCH3, NH2, NO2, SH, CN). R12 and R13 are H or unsubstituted alkyl/alkenyl/alkynyl.
R4 is OH, ═O (keto), or NH2, with an explicit allowance for ester/prodrug formatting when OH, and broad derivative selection when NH2 (amide/hydroxylamino/carbamate/urea/alkylamino/dialkylamino and salts).
R5 is H, C1-C6 alkyl, C2-C6 alkenyl, or (CH2)qR14 (q = 0 to 5) where R14 is cycloalkyl/heterocycloalkyl/aryl/heteroaryl with optional substitution (halogen, OH, OCH3, NH2, NO2, SH, CN).
W is C(O), C(S), or SO2.
R6 is cycloalkyl/heterocycloalkyl/aryl/heteroaryl with extremely broad substituent tolerance including:
- hetero-functional groups (OR15, SR15, SO2R15, SO2NR15R16, sulfonamide-like structures, etc.),
- carbonyl/ester/amides (C(O)R15, C(O)SR15, C(O)NR15R16, CO2R15, etc.),
- phosphonate-type P(O)(OR15)(OR16),
- and broad categories of hydrocarbon and heteroaryl substituents.

Most important functional limitation in the landscape context: Claim 1 is not constrained to a single viral target like RT or protease. It is constrained to a chemotype and method context (experienced patients, possible wild-type, protease-mutant, reverse-transcriptase-mutant; plus a resistance-fitness concept appears more explicitly in Claims 16 and 34).

Claim 16: Method of inhibiting mutant retroviral infection with “lower fitness” evolving from the infecting HIV

Claim 16 switches from general “treating HIV infection” to a mutant retrovirus framework and adds a fitness-lowering concept:

Method: inhibiting a mutant retroviral infection in a mammal infected with mutant retrovirus.
Administration: compound of a related formula (still tied to a structural formula, but with narrowed variable lists compared to Claim 1).
Functional limitation: “wherein a mutant virus that is capable of evolving from the HIV virus infecting said mammal has lower fitness, relative to said HIV virus infecting said mammal, in the presence of said compound, or pharmaceutically acceptable salt.”

Dependent claim expansion in the mutant context:

Claim 17: multidrug-resistant mutant retrovirus.
Claim 18: multidrug-resistant HIV.
Claim 19: multidrug-resistant HIV-1.
Claim 20: resistant to at least one antiviral agent among ritonavir, indinavir, amprenavir, saquinavir.
Claims 31, 29, 26-28, etc. specify mutation and aryl substitution examples tied to the chemotype.

Claim 34: Preventing development of drug resistance via “lower fitness”

Claim 34 parallels Claim 16 but is framed as prevention of drug resistance development:

Method: preventing development of drug resistance in an HIV-infected mammal.
Administration: compound of a formula with additional simplifications (Y/Z and X lists simplified similarly to Claim 16).
Functional limitation: again includes “mutant virus capable of evolving ... has lower fitness” relative to the infecting virus in presence of the compound.

Claim 32-33, 50-53, 52-57 add combination administration of at least one other antiviral agent, with ritonavir singled out in several dependents.

How Broad Is the Chemical Scope Versus the Clinical Scope?

Chemical breadth: intentionally wide, then narrowed

The claim architecture follows a common strategy:
1) Independent claims define a general chemotype family with expansive substitution options and derivative formats.
2) Dependent claims narrow ranges and specify exemplar substituents and ring-size limitations.

For Claim 1, dependent Claim 2 tightens several variables to specific ranges:

R1
- C1-C6 alkyl when alkyl
- C2-C6 alkenyl when alkenyl
- 4-7 membered ring when cycloalkyl/heterocycloalkyl/aryl/heteroaryl
R7, R8, R9
- C1-C6 unsubstituted alkyl when unsubstituted alkyl
- C2-C6 unsubstituted alkenyl when unsubstituted alkenyl
R3 and R11: 4-7 membered ring
R12/R13: C1-C6 unsubstituted alkyl or C2-C6 unsubstituted alkyl (even though the claim says “alkenyl,” it is in the dependent narrowing language)
R14 and R6: 4-7 membered ring when substituted with corresponding ring types
Substituent carbon counts capped for certain substitutions: “one to six carbon atoms” for alkyl/alkylthio/alkylamino substituents on R6.

Clinical breadth: method-of-use hooks for resistance and treatment-experienced status

Across the claims, the clinical coverage is broad but anchored with specific contexts:

Antiretroviral treatment-experienced mammals (Claim 1).
Wild-type HIV (Claim 13).
Mutant HIV with protease mutations (Claim 14).
Mutant HIV with reverse transcriptase mutations (Claim 15).
Multidrug-resistant HIV-1 (Claim 19).
Resistance to ritonavir/indinavir/amprenavir/saquinavir (Claim 20; repeated in Claim 29 and Claim 46-type dependent set).
Specific protease mutation set: V82F, I84V, G48V, V82A (Claim 31).
Fitness suppression of evolvable mutants (Claims 16 and 34).

Where Are the Specific Embodiments Inside the Claims?

The claim set includes multiple dependent claims that narrow to explicit substituent choices, especially around an Ar phenyl group and substitution positions.

Claim 4-12: exemplar compounds with Ar substitution

While the chemical structures are presented in the claims as formulas (not fully legible in the text dump you provided), the dependents identify an “Ar” aryl group and list substitution patterns.

Claim 5: “Ar is a phenyl which is optionally substituted with … methyl, amino, hydroxy, methoxy, methylthio, hydroxymethyl, aminomethyl, and methoxymethyl.”
Claim 9-11: Ar phenyl substituted at para, meta, or ortho positions.
Claim 12: Ar selected from para-aminophenyl, para-toluoyl, para-methoxyphenyl, meta-methoxyphenyl, meta-hydroxymethylphenyl.
Claim 8: R5 is isobutyl.
Claim 7: X is oxygen.

Claim 21-29: mutant retrovirus inhibition with defined Ar patterns

Claim 21 and 22 constrain the compound formula and define Ar substituents:

Claim 21: Ar is a phenyl, unsubstituted or substituted with methyl, amino, hydroxy, methoxy, methylthio.
Claim 22: Ar phenyl, unsubstituted or substituted with methyl, amino, methoxy, methylthio.
Claim 26: Ar selected from p-aminophenyl, p-methoxyphenyl, p-tolyl.
Claim 27: Ar is p-aminophenyl.
Claim 28: Ar is p-methoxyphenyl.
Claim 29: multidrug-resistant profile includes resistance to ritonavir/indinavir/amprenavir/saquinavir.

Claim 31: specific protease mutation set

Claim 31: “multidrug-resistant HIV-1 comprises a protease with at least one mutation selected from V82F, I84V, G48V and V82A.”

Claim 32-33 and 50-57: combination therapy options

Combination claims broaden commercial strategy:

Claim 32: further administration of at least one other antiviral agent selected from ritonavir, indinavir, amprenavir, saquinavir.
Claim 33: the other antiviral agent is ritonavir.
Claim 50-51 repeat this pattern (other antiviral agent is ritonavir).
Claim 52-57 repeat additional combinations for the treatment-resistance/prevent-resistance methods.

How to Read the Claim-Set “Strategy” for Investment or R&D Positioning

1) The patent tries to prevent design-around by using combinatorial structural variables

The independent claims define an interconnected set of variable positions (R1, R2, R3, R4, R5, R6 plus atom-type lists for Y/Z, and heteroatom/carbonyl toggles via Q/W and bond types via X). This makes a simple “swap one substituent” design-around less effective because substitution categories are permissive and include many functional group classes.

2) The patent also attempts to capture clinical differentiation through method framing

Instead of relying only on chemical structure, the claim set uses:

“antiretroviral treatment-experienced,”
“wild-type,”
“protease mutation” vs “reverse transcriptase mutation,”
and mutant inhibition framed around fitness reduction for evolvable mutants.

That mix can matter for enforcement because it can align the claim with how clinical outcomes are described in studies and submissions.

3) Fitness-lowering for evolvable mutants creates a second axis of infringement

Claims 16 and 34 include a functional statement about evolvable mutant virus fitness in the presence of the compound. That can be used in enforcement narratives even if the exact resistant genotype is not tested at the time the compound is administered, so long as the method is performed in the required context.

What Does This Imply for the Patent Landscape?

Landscape positioning

Based on the claim structure and clinical framing, US 8,597,876 appears to target the segment where companies pursued:

structurally related antivirals meant to cover resistance across known mutation classes,
and an approach to reduce or suppress fitness of evolving mutants under drug pressure.

In practice, patents like this typically overlap with:

earlier protease inhibitor and reverse transcriptase inhibitor families (as clinical comparator lists),
and later “next-gen” chemotypes that seek to retain efficacy against resistance while improving tolerability and resistance barriers.

How competitors likely face overlap risk

The high overlap risk areas are:

antiretroviral-experienced patients and resistance contexts (Claims 1, 13-15, 19-20, 29).
compositions and esters/salts/prodrugs (all independent claims).
combination therapy with at least one other antiviral agent in the specific listed set (Claims 32-34, 50-53, 52-57).

What competitors can target for design-around (within this claim text)

Even without additional patent-doc retrieval, the claim text indicates potential levers:

changes that move outside the defined lists for Y/Z, Q/W, or X;
changes that alter R4 formatting (especially derivatives of OH/keto/amine);
removal of the fitness-lowering method framing if enforcement requires the “lower fitness evolvable mutant” element.

However, because the claims are broad on functional substituents and allow many hetero-functional groups, narrow chemical modifications may still fall within the claim family if they remain within the defined variable sets.

Claim Scope Map (Quick Reference)

Claim	Purpose	Patient/Virus Context	Key limiting feature(s)
1	Treat HIV infection	Antiretroviral treatment-experienced mammals; wild-type; protease-mutant; RT-mutant via dependents	Administration of formula A compound (broad scaffold/substituent variable coverage)
13-15	Dependent narrowing	Wild-type HIV; protease mutation; reverse transcriptase mutation	Uses Claim 1 compound in specific viral mutation contexts
16	Inhibit mutant retroviral infection	Mutant retrovirus evolving in presence of compound	Evolvable mutant has “lower fitness” in presence of compound
17-20	Dependent narrowing	Multidrug-resistant; HIV-1; resistance to ritonavir/indinavir/amprenavir/saquinavir	Adds specific resistance scope via dependents
21-28	Dependent narrowing	Mutant inhibition with defined Ar substitution patterns	Limits phenyl substituents (para/meta/ortho selection, specified substituent sets)
29	Dependent narrowing	Resistance to ritonavir/indinavir/amprenavir/saquinavir	Reinforces specific drug-resistance group
31	Dependent narrowing	Protease mutation set	Adds V82F, I84V, G48V, V82A
32-33	Combination	Add other antiviral agents	Includes ritonavir as specific example
34	Prevent drug resistance development	HIV-infected mammal under drug pressure	Evolvable mutant has “lower fitness”
50-57	Combination dependents	Repeat combination strategy	Other antiviral agent includes ritonavir as specific example

(Claims and conditions based strictly on the claim text provided.)

Key Takeaways

US 8,597,876 is a chemotype-family patent: the independent claim(s) cover a broad structural formula (formula A) with extensive substitution permissiveness and allow salts, prodrugs, and esters.
The clinical framing targets antiretroviral treatment-experienced mammals and adds explicit mutant contexts: protease mutations, reverse transcriptase mutations, and multidrug-resistant HIV-1 with resistance to ritonavir/indinavir/amprenavir/saquinavir.
Claims 16 and 34 add a second infringement axis through the “lower fitness” limitation for evolvable mutants.
The claim set includes multiple dependent embodiments that narrow to Ar phenyl substitution patterns (para/meta/ortho) and fixed substituent examples (e.g., R5 = isobutyl) plus a specific protease mutation set (V82F, I84V, G48V, V82A).
The patent’s combination dependents allow commercial deployment alongside listed HIV drugs, including ritonavir.

FAQs

1) Does US 8,597,876 claim a single compound or a family?

It claims a family of compounds defined by a large structural formula (formula A) plus permitted salts, prodrugs, and esters, with dependent claims narrowing to specific substituent patterns.

2) What makes Claims 16 and 34 distinct from standard “inhibition” claims?

They include a functional “lower fitness” limitation for mutant viruses capable of evolving in the presence of the compound.

3) What resistance profiles are explicitly named?

The claims reference multidrug-resistant HIV-1 and resistance to ritonavir, indinavir, amprenavir, and saquinavir, and they specify a protease mutation set (V82F, I84V, G48V, V82A).

4) Are combination therapies within scope?

Yes. The claims include dependents requiring or permitting further administration of another antiviral, including ritonavir.

5) Where do the claims narrow chemically in a way a design-around could be assessed?

Dependent claims narrow variable classes by ring size (4-7 membered rings), alkyl/alkenyl chain length ranges (e.g., C1-C6, C2-C6), and specific aromatic substitution patterns (para/meta/ortho phenyl substitutions and enumerated Ar substituent sets).

References

[1] United States Patent 8,597,876. Claims text provided in prompt.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	500823	⤷ Start Trial
Australia	4828099	⤷ Start Trial
Australia	4828199	⤷ Start Trial
Australia	771780	⤷ Start Trial
Canada	2336160	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,597,876

Summary for Patent: 8,597,876